We conducted an open label , superiority , parallel design , randomized phase II trial comparing oral MCT [ daily celecoxib ( 200mg twice daily ) and weekly methotrexate ( 15mg/m ( 2 ) ) ] to intravenous single agent cisplatin ( IP ) ( 75mg/m ( 2 ) ) given 3 weekly .